Home World News First-Line Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab Continue to Demonstrate OS... World News First-Line Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab Continue to Demonstrate OS Benefit in Patients with Advanced Oesophageal Squamous Cell Carcinoma By Ogkologos - September 1, 2026 90 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the 5-year follow-up of the CheckMate 648 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Researchers Find a Way to Prevent Cancer Cells from Taking in... July 14, 2020 FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or... May 9, 2025 Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian September 4, 2026 Treatment with Nivolumab and Low-Dose Ipilimumab is Effective and Tolerable in... April 8, 2022 Load more HOT NEWS How you can do your part in the AI transformation of... England: Smoking responsible for twice as many cancers in most deprived... “My First Thought Was My Children:” Young Mom Diagnosed With Triple-Negative... EMA Recommends Extension of Indications for Ponatinib Associated with a New...
